

**5.0 510(k) Summary****1. Sponsor**

JUN 30 2010

SpineFrontier, Inc.  
500 Cummings Center  
Suite 3500  
Beverly, MA 01915

**Primary Contact:** John Sullivan  
**Telephone:** 1- 978-232-3990

**Date Prepared:** May 29, 2009

**2. Device Name and Classification:**

Proprietary Name:	<b>S-LIF™ Intervertebral Body Fusion Device, S-LIF™ IBC, S-LIF™ IBF</b>
Common/Usual Name:	Intervertebral Fusion Device With Bone Graft, Lumbar
Classification Name:	Intervertebral Fusion Device With Bone Graft, Lumbar, (21 CFR 888.3080), Class II
Product Code:	MAX

**3. Predicate Devices**

K072289 – SpineFrontier Inc., Dorado Intervertebral Body Cage  
K071795 – Nuvasive CoRoent System  
K072791 – Synthes Spine Oracle Spacer

**4. Device Description**

The **S-LIF™ Intervertebral Body Fusion Device** is a spinal intervertebral body fusion device intended for intervertebral body fusion of the spine of skeletally mature patients, using autogenous bone graft to facilitate fusion. The device is indicated for use in patients with degenerative disc disease (DDD) at one or two contiguous spinal levels from L2-S1. The system is comprised of devices made of PEEK Optima®, with a fixed width and various lengths and heights to fit the anatomical needs of a wide variety of patients. The device has raised contours on the superior and inferior surfaces that will resist device movement following implant

## 5. Intended Use

The **S-LIF™ Intervertebral Body Fusion Device** is a spinal intervertebral body fusion device intended for intervertebral body fusion of the spine of skeletally mature patients, using autogenous bone graft to facilitate fusion. The device is indicated for use in patients with degenerative disc disease (DDD) at one or two contiguous spinal levels from L2-S1. These DDD patients may also have up to Grade I spondylolisthesis or retrolithesis at the involved level(s).

The SpineFrontier **S-LIF™ Intervertebral Body Fusion Device** is intended to be used with supplemental spinal fixation system(s) cleared for use in the lumbar spine.

Degenerative disc disease is defined as discogenic back pain with degeneration of the disc confirmed by history or radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment.

## 6. Technological Characteristics

The SpineFrontier **S-LIF™ Intervertebral Body Fusion Device** was shown to be substantially equivalent to predicate devices through comparison of indications for use, function, operating principles, and materials.

## 7. Basis for Substantial Equivalence

The **S-LIF™ Intervertebral Body Fusion Device** was evaluated in accordance with FDA Document, *Class II Special Controls, Guidance Document: Intervertebral Fusion Device, June 12, 2007*, and has been found to meet criteria defined in the guidance document; and has been demonstrated to be substantially equivalent to predicate devices in terms of indications for use, function, materials, and performance (mechanical testing). Clinical data was not required for this device. Mechanical test comparisons were conducted per the following standard test methods:

- ASTM F2077-03, Static and Dynamic Axial Compression, Static Torsion, and Static and Dynamic Shear Compression
- ASTM F2267-04, Subsidence Under Static Axial Compression
- ASTM Draft Standard F-04.25.02.02, Static Expulsion



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room - WO66-G609  
Silver Spring, MD 20993-0002

JUN 30 2010

SpineFrontier, Inc.  
% Mr. John Sullivan  
500 Cummings Center  
Beverly, Massachusetts 01915

Re: K092815

Trade/Device Name: S-LIF™ Intervertebral Body Fusion Device  
Regulation Number: 21 CFR 888.3080  
Regulation Name: Intervertebral body fusion device  
Regulatory Class: Class II  
Product Code: MAX  
Dated: June 21, 2010  
Received: June 21, 2010

Dear Mr. Sullivan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Mark N. Melkerson  
Director  
Division of Surgical, Orthopedic  
and Restorative Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

#### 4.0 Indications for Use Statement

510(k) Number (if Known): K092815

##### Indications For Use:

The **S-LIF™ Intervertebral Body Fusion Device** is a spinal intervertebral body fusion device intended for intervertebral body fusion of the spine of skeletally mature patients, using autogenous bone graft to facilitate fusion. The device is indicated for use in patients with degenerative disc disease (DDD) at one or two contiguous spinal levels from L2-S1. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved level(s).


The SpineFrontier **S-LIF™ Intervertebral Body Fusion Device** is intended to be used with supplemental spinal fixation system(s) cleared for use in the lumbar spine.

Degenerative disc disease is defined as discogenic back pain with degeneration of the disc confirmed by history or radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment.

Prescription Use: X  
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use: \_\_\_\_\_  
(Part 21 CFR 807 Subpart C)

  
for (Division Sign-Off)  
Division of Surgical, Orthopedic,  
and Restorative Devices

510(k) Number K092815